Research Analysts Set Expectations for SPRO FY2024 Earnings

Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - Analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Spero Therapeutics in a research note issued to investors on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($1.23) per share for the year, down from their prior estimate of ($0.75). HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Spero Therapeutics' current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Spero Therapeutics' Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.84) EPS.

A number of other equities research analysts have also recently issued reports on the stock. TD Cowen reaffirmed a "hold" rating on shares of Spero Therapeutics in a report on Monday, November 18th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Spero Therapeutics in a report on Friday, November 15th.

Spero Therapeutics Stock Performance

NASDAQ SPRO traded up $0.02 on Wednesday, reaching $1.18. The company had a trading volume of 238,184 shares, compared to its average volume of 220,013. The firm has a market capitalization of $64.33 million, a price-to-earnings ratio of 17.07 and a beta of 0.59. Spero Therapeutics has a 1-year low of $1.01 and a 1-year high of $1.89. The company's fifty day moving average is $1.25 and its 200-day moving average is $1.32.

Institutional Trading of Spero Therapeutics

Large investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in shares of Spero Therapeutics during the 1st quarter worth approximately $31,000. Renaissance Technologies LLC boosted its position in shares of Spero Therapeutics by 14.2% during the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company's stock worth $1,269,000 after acquiring an additional 121,492 shares in the last quarter. Acadian Asset Management LLC boosted its position in Spero Therapeutics by 40.6% in the second quarter. Acadian Asset Management LLC now owns 1,071,860 shares of the company's stock valued at $1,392,000 after buying an additional 309,262 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Spero Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company's stock valued at $2,844,000 after buying an additional 9,675 shares in the last quarter. Institutional investors and hedge funds own 25.60% of the company's stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.